The Gut Microbiome - Source of Sepsis and Novel Target in Intensive Care Units? Research on Human Tissue, Body Fluids, Neuropsychological Assessment and Brain Imaging

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Here, the investigators propose to study host responses to reduced microbiome complexity driven by treatment with broad spectrum antibiotics in patients with severe infections or sepsis. The proposal aims to combine holistic approaches with emerging experimental technologies to investigate the complex interactions between the gut microbiota and its host and assess the impact of specific bacterial communities on longevity and stress responses. A strong focus of this study will also be placed on microbiome dysbiosis and secondary impacts on short- and long-term brain dysfunction using clinical, laboratory and imaging procedures.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥ 18 years

• One of the following criteria

‣ Critically ill patients treated with meropenem or piperacillin/tazobactam started within the last 72 h

⁃ Critically ill patients without systemic antimicrobial therapy within the last 72 hours and an expected ICU length of stay of more than 3 days

⁃ Long-term survivors of sepsis, e.g. from pre-existing sepsis cohorts

Locations
Other Locations
Germany
Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Jena
RECRUITING
Jena
Contact Information
Primary
Johannes Ehler, Priv.-Doz. Dr. med.
johannes.ehler@med.uni-jena.de
+49 36419323397
Backup
Katrin Ludewig, Dr. med.
katrin.ludewig@med.uni-jena.de
+49 36419323378
Time Frame
Start Date: 2024-12-27
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 100
Treatments
ICU patients with antibiotic treatment
ICU patients treated with piperacillin/tazobactam or meropenem
ICU patients without antibiotic treatment
ICU patients without antibiotic treatment during their ICU stay
Long-term survivors of critical illness
Long-term survivors at least six months or more after the beginning of critical illness.
Related Therapeutic Areas
Sponsors
Collaborators: Friedrich Schiller University of Jena
Leads: Jena University Hospital

This content was sourced from clinicaltrials.gov

Similar Clinical Trials